MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September
08 September 2022 - 06:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
survival outcomes for patients with cancer, today announced
that Hervé Affagard, CEO and co-founder of MaaT Pharma, and Siân
Crouzet, CFO of MaaT Pharma, will participate in three upcoming
investor conferences.
Details for the events are as follow:
H.C. Wainwright 24th Annual Global Investment Conference
(hybrid format)
- Format: virtual presentation & investor meetings
- Presentation date: Hervé Affagard will present the Company and
provide a corporate update.
The presentation will be available on-demand through the
H.C. Wainwright conference portal, starting at 7:00 am EST/1:00 pm
CET on Monday, September 12, 2022. A replay will be
available on the investor page of Maat Pharma’s website:
https://www.maatpharma.com/investors/
- Link: https://hcwevents.com/globalconference/#toggle-id-4
KBC Securities Life Sciences conference (virtual)
- Format: virtual investor meetings
- Date: Thursday, September 15 and Friday,
September 16, 2022
5th edition of the “FORUM Lyon Pôle Bourse Valeurs
Régionales” (on-site event)
- Format: investor meetings
- Date: Wednesday, September 28, 2022
- Location: Lyon, France
- Link: https://forum.lyonpolebourse.com/form.aspx
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma launched in March
2022 in Europe, a Phase 3 clinical trial for patients with acute
GvHD, following the achievement of its proof of concept in a Phase
2 trial. Its powerful discovery and analysis platform, gutPrint®,
supports the development and expansion of its pipeline by
determining novel disease targets, evaluating drug candidates, and
identifying biomarkers for microbiome-related conditions. The
company’s Microbiome Ecosystem Therapies are produced through a
standardized cGMP manufacturing and quality control process to
safely deliver the full diversity of the microbiome, in liquid and
oral formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice.
MaaT Pharma is the first company developing microbiome-based
therapies listed on Euronext Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220908005768/en/
MaaT Pharma – Investor Relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 07 55 25 36
prichaud@maat-pharma.com
Trophic Communications – Corporate and Medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 89
2070 89831 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Mär 2023 bis Mär 2024